Eugia Pharma Specialties receives USFDA approval for Bortezomib for Injection

7 May 2022 , 01:33 AM

Aurobindo Pharma announced that its wholly owned subsidiary company Eugia Pharma Specialties has received a final approval from the US Food Drug Administration USFDA to manufacture and market Bortezomib for injection 35 mg Bortezomib for Injection 35 mgvial Single-Dose Vial to be bioequivalent and therapeutically equivalent to the Velcade for Injection 35 mgvial of Takeda Pharmaceuticals USA Inc The product is being launched immediately The approved product has a market size of US$ 1172 million for the twelve months ending March 2022 according to IQVIA Bortezomib for injection is indicated for the treatment of Adult patients with multiple myeloma cancer of plasma cells Also used to treat adult patients with mantle cell lymphoma cancer of lymph nodes